Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
Labidi-Galy SI, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T, Combes JD, Heimgartner-Hu K, Tredan O, Guevara H, Heudel PE, Reverdy T, Bazan F, Heinzelmann-Schwarz V, Fehr M, de Castelbajac V, Vaflard P, Crivelli L, Bonadona V, Viassolo V, Buisson A, Golmard L, Rodrigues M, Ray-Coquard I. Labidi-Galy SI, et al. Among authors: de castelbajac v. Gynecol Oncol. 2019 Nov;155(2):262-269. doi: 10.1016/j.ygyno.2019.09.008. Epub 2019 Oct 8. Gynecol Oncol. 2019. PMID: 31604666
Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy.
Hours A, Toussaint A, De Castelbajac V, Sautter C, Borghese J, Frank S, Coussy F, Laas E, Grandal B, Dumas E, Daoud E, Guerin J, Balezeau T, Feron JG, Fourchotte V, Kirova Y, Lerebours F, Pierga JY, Guillot E, Santulli P, Grynberg M, Sonigo C, Reyrat E, Soibinet-Oudot P, Reyal F, Hamy AS. Hours A, et al. Among authors: de castelbajac v. Front Oncol. 2021 Sep 28;11:701620. doi: 10.3389/fonc.2021.701620. eCollection 2021. Front Oncol. 2021. PMID: 34650912 Free PMC article.
Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.
Abbar B, De Castelbajac V, Gougis P, Assoun S, Pluvy J, Tesmoingt C, Théou-Anton N, Cazes A, Namour C, Khalil A, Gounant V, Besse B, Zalcman G, Brosseau S. Abbar B, et al. Among authors: de castelbajac v. Lung Cancer. 2021 Feb;152:109-118. doi: 10.1016/j.lungcan.2020.12.026. Epub 2020 Dec 28. Lung Cancer. 2021. PMID: 33385736